Evidence map›Paper›PMID 40455815›Full record

ArticleFuture oncology (London, England)2025

rechARge: a randomized phase III trial of the androgen receptor ligand-directed degrader, BMS-986365, vs investigator's choice in patients with mCRPC.

Kim Nguyen Chi, Rana R McKay, Shahneen Sandhu, Jose A Arranz, Philippe Barthélémy, Boris Hadaschik, Nobuaki Matsubara, Neal D Shore, Dingwei Ye, Teresa Cascella and 4 more

Abstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Kim Nguyen ChiDepartment of Medical Oncology, BC Cancer Agency, Vancouver, Canada.
Rana R McKayDepartment of Medicine, University of California, San Diego, La Jolla, CA, USA.
Shahneen SandhuDepartment of Uro-oncology, Peter MacCallum Cancer Centre and the University of Melbourne, Melbourne, VIC, Australia.
Jose A ArranzDepartment of Medical Oncology, Gregorio Marañón University Hospital, Madrid, Spain.
Philippe BarthélémyOncology Department, University Hospital Strasbourg, Strasbourg, France.
Boris HadaschikDepartment of Urology, University of Duisburg-Essen, Essen, Germany.
Nobuaki MatsubaraDepartment of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Neal D ShoreDepartment of Urology, Carolina Urologic Research Center/AUC Urology Specialists, Myrtle Beach, SC, USA.
Dingwei YeDepartment of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.
Teresa CascellaDepartment of Research and Development, Bristol Myers Squibb, Boudry, Switzerland.
Irina IrincheevaDepartment of Research and Development, Bristol Myers Squibb, Boudry, Switzerland.
Stephanie KreiserDepartment of Clinical Science, Bristol Myers Squibb, Princeton, NJ, USA.
Antoine Thiery-VuilleminDepartment of Research and Development, Bristol Myers Squibb, Boudry, Switzerland.
Dana E RathkopfDepartment of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

There is an ongoing need for efficacious, life-prolonging therapies for males with metastatic castration-resistant prostate cancer (mCRPC). mCRPC that progresses after treatment with androgen receptor pathway inhibitors (ARPIs) may still be driven by AR signaling. BMS-986365 is a heterobifunctional, orally bioavailable ligand-directed degrader that targets the AR through a first-in-class dual mechanism of AR degradation and antagonism. Here, we present the study design of rechARge, a phase III, randomized, multicenter, adaptive, two-part, open-label trial evaluating BMS-986365 versus investigator's choice of therapy comprising either docetaxel or a switch to an alternative ARPI (abiraterone or enzalutamide) in patients with mCRPC whose disease has progressed after treatment with one prior ARPI. The primary study objective is to compare the efficacy and safety of BMS-986365 versus investigator's choice of therapy. Approximately 960 patients will be enrolled.

Indexed as

Androgen Receptor AntagonistsProstatic Neoplasms, Castration-ResistantReceptors, AndrogenAdaptive Clinical Trials as TopicAndrostenesBenzamidesClinical Trials, Phase III as TopicDocetaxelHumansMaleMulticenter Studies as TopicNitrilesPhenylthiohydantoinRandomized Controlled Trials as TopicTreatment OutcomeabirateroneAndrogen Receptor AntagonistsAndrostenesAR protein, humanBenzamidesDocetaxelenzalutamideNitrilesPhenylthiohydantoinReceptors, Androgenandrogen receptorBMS‑986365clinical trialligand-directed degradermetastatic castration resistant prostate cancerphase IIIprotein degradationprotocol

Identifiers

PMID40455815
PMCPMC12150650

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.